Kingdon Capital Management, L.L.C. Syndax Pharmaceuticals Inc Transaction History
Kingdon Capital Management, L.L.C.
- $834 Million
- Q3 2024
A detailed history of Kingdon Capital Management, L.L.C. transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Kingdon Capital Management, L.L.C. holds 1,000,000 shares of SNDX stock, worth $12.5 Million. This represents 2.31% of its overall portfolio holdings.
Number of Shares
1,000,000
Previous 894,993
11.73%
Holding current value
$12.5 Million
Previous $18.4 Million
4.77%
% of portfolio
2.31%
Previous 2.13%
Shares
3 transactions
Others Institutions Holding SNDX
# of Institutions
228Shares Held
88.4MCall Options Held
1.01MPut Options Held
692K-
Black Rock Inc. New York, NY7.91MShares$99 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ5.84MShares$73.2 Million9.23% of portfolio
-
Wellington Management Group LLP Boston, MA4.99MShares$62.4 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.89MShares$61.2 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY4.11MShares$51.4 Million6.25% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $708M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...